Tiba Biotech has announced a major scientific milestone with the development of the world’s first RNA vaccine against Foot-and-Mouth Disease (FMD). This achievement was recently featured on Landline, the Australian Broadcasting Corporation’s flagship program covering rural and regional affairs.
The $400,000 SBIR Phase I award will support development of Tiba’s tissue-targeted delivery platform and proprietary enhanced self-amplifying RNA payloads.
Tiba announced the results of a challenge study evaluating the efficacy of a novel vaccine for Foot and Mouth Disease (FMD) in cattle using Tiba’s RNABL™ delivery platform.
BARDA highlights Tiba in a new FASTx program to accelerate the development of early-stage antiviral platforms with multiple collaborators
Tiba announces a BARDA FASTx award to develop an RNAi-based therapeutic for H1N1 influenza that targets the highly conserved viral nucleoprotein using Tiba’s novel RNABL™ delivery platform
The government of NSW (Australia) is investing in a range of animal disease vaccines with leading institutions and technology providers, including Tiba Biotech. A pilot project intended to fast-track an mRNA vaccine for border disease virus (BDV) has been successfully manufactured for the first time in NSW.
Tiba Biotech has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and Development Authority (‘BARDA’), to apply our next-generation nucleic acid delivery technology to develop new products that can guard against and respond to public health threats.
Tiba Biotech was mentioned in the recent edition of THE VIRAL MOST WANTED, a series of articles by the Coalition for Epidemic Preparedness Innovations (CEPI), highlighting progress toward the development of next generation flavivirus vaccines.
Tiba Biotech receives an NIH Phase II SBIR grant to continue its development of a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
This article, appearing in Scrip’s Tech Transfer Roundup, reports on Tiba Biotech and CEPI planning ahead for the next pandemic.
© 2024 Tiba Biotech LLC. All rights reserved
